Y-Intercept (HK)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Y-Intercept (HK)’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.98M	Sell	6,561 -4,800	-42%	-$1.45M	0.04%	714
2026 Q1	$3.76M	Buy	+11,361	New	+$3.87M	0.07%	437
2025 Q4	–	Sell	-2,614	Closed	-$1.19M	–	1506
2025 Q3	$1.19M	Buy	+2,614	New	+$1.06M	0.03%	892
2025 Q2	–	Sell	-3,720	Closed	-$1M	–	1610
2025 Q1	$1M	Sell	3,720 -796	-18%	-$205K	0.07%	404
2024 Q4	$1.06M	Buy	+4,516	New	+$1.19M	0.07%	403
2024 Q3	–	Sell	-46,388	Closed	-$11.3M	–	1269
2024 Q2	$11.3M	Buy	46,388 +43,545	+1,532%	+$6.87M	0.62%	11
2024 Q1	$425K	Buy	2,843 +988	+53%	+$165K	0.03%	796
2023 Q4	$355K	Buy	+1,855	New	+$316K	0.03%	757
2022 Q4	–	Sell	-5,935	Closed	-$1.19M	–	972
2022 Q3	$1.19M	Buy	+5,935	New	+$1.13M	0.12%	267
2022 Q1	–	Sell	-3,134	Closed	-$531K	–	706
2021 Q4	$531K	Buy	+3,134	New	+$582K	0.13%	235
2021 Q3	–	Sell	-7,592	Closed	-$1.29M	–	629
2021 Q2	$1.29M	Buy	7,592 +3,832	+102%	+$561K	0.33%	59
2021 Q1	$508K	Buy	+3,760	New	+$566K	0.14%	254

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Y-Intercept (HK)'s ALNY Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Alnylam Pharmaceuticals (ALNY) stake by 42% in Q2 2026, selling an estimated $1.45M and leaving 6,561 shares worth $1.98M. The position accounts for 0.04% of the portfolio, ranked #714.

Y-Intercept (HK) first reported a position in ALNY in Q1 2021 and has held it in 12 quarters since. The position peaked at $11.3M in Q2 2024. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Y-Intercept (HK) held 6,561 shares of Alnylam Pharmaceuticals worth $1.98M as of Q2 2026.
Y-Intercept (HK) sold 4,800 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.45M.
Alnylam Pharmaceuticals made up 0.04% of Y-Intercept (HK)'s portfolio in Q2 2026, its #714 holding.
Y-Intercept (HK) first reported a position in Alnylam Pharmaceuticals in Q1 2021 and has held it in 12 quarters since.
Y-Intercept (HK)'s Alnylam Pharmaceuticals position peaked at $11.3M in Q2 2024.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.